TYPE 2 DIABETES AND OMEGA 3
Study published in July 2017 shows the omega-3
- polyunsaturated fatty acids (PUFAs)
- eicosapentaenoic acid (EPA) and
- docosahexaenoic acid (DHA)
reduce levels of albuminuria* in patients with type 2 diabetes mellitus.
*High concentrations of albumin in urine indicate inflammation and independently predict morbidity and mortality from cardiovascular disease.
Researchers randomly assigned 262 patients with stable coronary artery disease, 30% of whom had type 2 diabetes, to receive either
- 1.86 grams of EPA and 1.5 grams of DHA daily
- or no omega-3 PUFAs
for 1 year. The percent change in urine albumin-to-creatinine ratio (ACR) was determined in both groups.
- In individuals without diabetes, no change was detected in urine ACR in either the omega-3 or the control group.
- In participants with diabetes who did not receive omega-3 PUFAs, a 72.3% rise in ACR was observed.
- Diabetic patients ingesting the omega-3 PUFAs did not experience any change in ACR. No change in urine ACR was observed in patients with type 2 diabetes who were taking an angiotensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker while also supplementing with omega-3 PUFAs, whereas a 64.2% increase in ACR occurred in those not supplementing with omega-3 PUFAs.
The rise in ACR was directly associated with an increase in systolic blood pressure.
The researchers concluded, “EPA and DHA supplementation attenuated progression of albuminuria in subjects with type 2 diabetes mellitus and coronary artery disease, most of whom were on an angiotensin-converting enzyme-inhibitor or angiotensin-receptor blocker.
Thus, EPA and DHA supplementation should be considered as additional therapy to an angiotensin-converting enzyme-inhibitor or angiotensin-receptor blocker in subjects with type 2 diabetes mellitus and coronary artery disease.”
Elajami TK, et al. J Am Heart Assoc. 2017;6:e004740.
- maryann stanger